COPENHAGEN/LONDON (Reuters) - Obesity drug-maker NovoNordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and ...
Some results have been hidden because they may be inaccessible to you